81,349 results on '"Hypoglycemia"'
Search Results
202. Accidental Once-Daily Use of Dulaglutide: A Case Report.
- Author
-
Moore, Hannah E., Zaya, Viva, Burns, Carly V., and Berlie, Helen D.
- Subjects
- *
GLUCAGON-like peptide-1 agonists , *DRUG overdose , *SUBSTANCE abuse , *INSULIN , *TELEMEDICINE , *TYPE 2 diabetes , *MEDICATION therapy management , *HYPOGLYCEMIA - Abstract
The article focuses on the accidental daily use of the weekly GLP-1 receptor agonist dulaglutide, detailing a case where a patient used it daily for six days, resulting in multiple hypoglycemic episodes. Topics include the patient's medical history and medication regimen, factors contributing to the dosing error (such as insurance changes and medication samples), and clinical management strategies following the error.
- Published
- 2024
- Full Text
- View/download PDF
203. Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review.
- Author
-
Russell‐Jones, David, Bailey, Timothy S., Lane, Wendy, Mathieu, Chantal, and Pedersen‐Bjergaard, Ulrik
- Subjects
- *
INSULIN therapy , *TYPE 1 diabetes , *GLYCOSYLATED hemoglobin , *DISEASE management , *PHARMACEUTICAL chemistry , *INSULIN , *INSULIN pumps , *INJECTIONS , *HYPOGLYCEMIA , *BLOOD sugar monitoring - Abstract
Aim: To summarise, in a narrative review, published data on hypoglycaemia occurrence with basal insulin therapy in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target randomised controlled trials. Methods: Data were included from 21 eligible trials, which mainly used self‐measured blood glucose or plasma glucose to detect hypoglycaemia. Results: All‐day self‐measured blood glucose or plasma glucose level 2 (glucose threshold of 3.1 or 3.0 mmol/L) and level 3 (severe, requiring assistance) hypoglycaemic events were reported, respectively, by a range of 69.0%–97.5% and 0%–13.4% adults when receiving basal‐bolus insulin therapy, with rates of 10.6–68.1 and 0.0–0.4 events per patient‐year of exposure, respectively. Hypoglycaemia rates measured using continuous glucose monitoring (three studies) were numerically, yet consistently, higher than with either other method, except when limiting to symptomatic events. Nocturnal hypoglycaemia rates were generally less than 30% of the equivalent all‐day rates. Conclusions: Differences across the studies in design (e.g., titration targets) and participant characteristics hindered comparison of hypoglycaemia rates by insulin formulation. Consequently, few trends were identified by insulin formulation, study methodology or individuals' characteristics, suggesting that further research is required to identify treatment strategies that facilitate development of individualised recommendations to lower hypoglycaemia risk. These findings are useful to understand hypoglycaemia risk with available basal insulin therapies when used in a multiple daily injection regimen, as well as to provide context for the results of ongoing and future clinical trials, including those for two once‐weekly basal insulins, insulin icodec and basal insulin Fc. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
204. A register‐based study describing time trends in risk factor control and serious hypoglycaemia together with the effects of starting continuous glucose monitoring in people with type 1 diabetes in Norway.
- Author
-
Sølvik, Una Ørvim, Cooper, John Graham, Løvaas, Karianne Fjeld, Ernes, Tony, Madsen, Tone Vonheim, Sandberg, Sverre, and Ueland, Grethe Åstrøm
- Subjects
- *
TYPE 1 diabetes , *RISK assessment , *CROSS-sectional method , *GLYCOSYLATED hemoglobin , *GLYCEMIC control , *REPORTING of diseases , *DESCRIPTIVE statistics , *SURVEYS , *LONGITUDINAL method , *LOW density lipoproteins , *CONTINUOUS glucose monitoring , *CONFIDENCE intervals , *BLOOD pressure , *COMPARATIVE studies , *HYPOGLYCEMIA , *DISEASE risk factors - Abstract
Aims: To describe trends in risk factor control and serious hypoglycaemia in people with type 1 diabetes and to assess the effect of starting continuous glucose monitoring (CGM) in the real‐world setting. Methods: Two cross‐sectional surveys including 5746 individuals in 2012 and 18,984 individuals in 2020 based on data recorded in the Norwegian Diabetes Register for Adults (NDR‐A) and an analysis of a longitudinal cohort of 2057 individuals where data on CGM and HbA1c were available in the NDR‐A in 2012 and 2020. Results: In the cross‐sectional surveys mean HbA1c decreased from 66 mmol/mol (99% CI 65, 66) (8.2%) in 2012 to 61 mmol/mol (99% CI 61, 61) (7.7%) in 2020 (p < 0.0001). The proportion reporting serious hypoglycaemia decreased from 16.9 to 6.2% in 2020 (p < 0.0001). Mean LDL‐cholesterol decreased from 2.80 (99% CI 2.78, 2.83) to 2.63 (99% CI 2.61, 2.65) mmol/l in 2020 (p < 0.0001). Mean blood pressure increased slightly. In the CGM cohort, we found a 3 mmol/mol (0.3%) greater improvement in mean HbA1c and a greater reduction in serious hypoglycaemia (−12.3% vs. −6.2%) among individuals that had started using CGM between 2013 and 2020 when compared with individuals that had not started using CGM. Conclusions: Between 2012 and 2020, we found marked improvements in glycaemic control and a considerable decrease in the proportion of individuals reporting serious hypoglycaemia. The proportion of individuals using CGM increased substantially and individuals that had started using CGM by 2020 showed greater improvement in glycaemic control and less serious hypoglycaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
205. SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.
- Author
-
Ramírez-Rincón, Alex, Henao-Carrillo, Diana, Omeara, Miguel, Oliveros, Julio, Assaf, José, Ordóñez, Jaime E., Prasad, Preethy, and Alzate, María Alejandra
- Subjects
- *
TYPE 2 diabetes , *GLUCAGON-like peptide-1 receptor , *GLYCEMIC control , *GLYCOSYLATED hemoglobin , *GLUCAGON-like peptide-1 agonists , *HYPERGLYCEMIA - Abstract
Introduction: Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination of insulin degludec (a basal insulin) and liraglutide (a glucagon-like peptide-1 receptor agonist [GLP-1RA]). This study aimed to investigate clinical outcomes in people with type 2 diabetes mellitus (T2DM) after initiating IDegLira treatment in a real-world setting in Colombia. Methods: SPIRIT is a non-interventional, single-arm, retrospective chart review study to assess clinical outcomes in people with T2DM. Participating patients were switched from a treatment regimen of basal insulin (with or without oral antidiabetics [OADs]) and started on treatment with IDegLira a minimum of 26 ± 6 weeks before the data collection start date. Data were collected from the medical records of 175 patients in ten clinical centers across Colombia. Results: Compared with baseline, there was a significant reduction in glycated hemoglobin (HbA1c) (1.3%; 95% confidence interval [CI] − 1.6 to − 1.0; p < 0.0001) after 26 ± 6 weeks of follow-up. The mean HbA1c at baseline and at the end of the study was 9.1% and 7.8%, respectively. In addition, IDegLira significantly reduced absolute body weight by 1 kg (95% CI − 1.5 to − 0.5; p < 0.0001), from a mean of 76.1 kg at baseline to 75.1 kg after follow-up. The mean IDegLira dose at the end of the study was 21.3 U, and no severe hypoglycemic events were observed during the follow-up period. Conclusion: In real-world practice, initiating IDegLira in patients with T2DM previously treated with basal insulin (± OAD) was associated with improved glycemic control, reduced body weight and reduced risk of hypoglycemia. Trial registration: ClinicalTrials.gov identifier: NCT05324462. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
206. Impacts of medication adherence and home healthcare on the associations between polypharmacy and the risk of severe hypoglycemia among elderly diabetic patients in Taiwan from 2002 to 2012: A nationwide case-crossover study.
- Author
-
Fan, Yu-Pei, Lai, Tzu-Hsuan, Lai, Jung-Nien, and Yang, Chen-Chang
- Abstract
• Polypharmacy use was associated with the risk of severe hypoglycemia. • Good adherence and receiving home healthcare services were associated with a decreased odds of severe hypoglycemic events in elderly diabetic patients. To assess how medication adherence and home healthcare support influence the role of polypharmacy in induced hypoglycemia events among elderly diabetic patients. This case-crossover study retrieved records on diabetic patients >=65 years with severe hypoglycemia from 2002 to 2012 in Taiwan. Case period defined as 1–3 days before severe hypoglycemia was compared with a preceding control period of the same length, with an all-washout period of 30 days. Moreover, the modifiable effects of medication adherence and home healthcare service use were evaluated by stratified analysis. Totally 2,237 patients were identified. Polypharmacy use was associated with the risk of severe hypoglycemia. Patients receiving polypharmacy without home healthcare services (aOR: 1.34; 95 % CI: 1.16–1.54) and those with poor adherence to anti-diabetic medications (aOR: 1.48; 95 % CI: 1.24–1.77) were significantly associated with an elevated risk of severe hypoglycemia. In patients with good adherence, non-home healthcare users being prescribed with polypharmacy had a higher risk of severe hypoglycemia. In the group that received home healthcare services, patients with poor adherence using polypharmacy had a higher risk of severe hypoglycemia. Good adherence and receiving home healthcare services were associated with a decreased odds of severe hypoglycemic events in elderly diabetic patients, regardless of the fact whether they were prescribed with polypharmacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
207. Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes.
- Author
-
Li-Nong JI and Yun-Dai CHEN
- Subjects
HYPERGLYCEMIA prevention ,BLOOD sugar analysis ,MEDICAL protocols ,WEIGHT loss ,SMOKING cessation ,GLUCAGON-like peptide-1 agonists ,COMBINATION drug therapy ,CORONARY disease ,GLYCOSYLATED hemoglobin ,BEHAVIOR modification ,PATIENT safety ,DRUG side effects ,ANTILIPEMIC agents ,GLYCEMIC control ,EXERCISE therapy ,DRUG administration ,CARDIOVASCULAR diseases risk factors ,HYPOGLYCEMIC agents ,TREATMENT effectiveness ,INSULIN ,ANTIHYPERTENSIVE agents ,ROUTINE diagnostic tests ,VOLUMETRIC analysis ,PERCUTANEOUS coronary intervention ,TYPE 2 diabetes ,SODIUM-glucose cotransporter 2 inhibitors ,HEALTH behavior ,MEDICAL screening ,GENERIC drug substitution ,PLATELET aggregation inhibitors ,PATIENT monitoring ,PERIOPERATIVE care ,ALGORITHMS ,MEDICAL practice ,TIME ,FASTING ,DIET ,HYPOGLYCEMIA ,HEALTH care teams ,MEDICAL referrals ,PATIENT aftercare ,COMORBIDITY ,DISEASE risk factors - Abstract
The prevalence of patients with coronary heart disease (CHD) and diabetes mellitus is notably high, posing significant residual cardiovascular risks even after routine interventions such as antihypertensive, lipid-lowering, and antithrombotic treatments. Recent studies have demonstrated that certain glucose-lowering medications confer cardiovascular benefits for patients with type 2 diabetes. However, a survey indicates that cardiologists may not be fully acquainted with the optimal screening timing, indicators, and diagnostic criteria for type 2 diabetes, and there is insufficient awareness and a low rate of prescription of novel glucose-lowering medications with proven cardiovascular efficacy, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i). In this context, based on domestic and international guidelines or consensus and the latest evidence-based evidence, this consensus aims to standardize the glycemic management for patients with acute coronary syndrome, chronic coronary syndrome, and perioperative management for percutaneous coronary intervention. It highlights the key points of screening and diagnosis of type 2 diabetes, and the comprehensive management of cardiovascular risk in patients with CHD. The consensus elaborates on the principles and algorithms of glycemic management for CHD patients, without involving acute complications of diabetes, clarifies the clinical practice of glucose-lowering medications with cardiovascular benefits, and promotes the standardized use of these medications in cardiovascular and other related specialty fields. Additionally, it addresses the glucose-lowering treatment to comprehensively reduce cardiovascular risks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
208. Approach to the Patient: Investigation of Pediatric Hypoglycemia in the Emergency Department—A Practical Algorithm.
- Author
-
Thornton, Paul S and Hawkes, Colin P
- Subjects
PEDIATRIC emergency services ,CHILD patients ,HYPERGLYCEMIA ,ALGORITHMS ,HYPOGLYCEMIA - Abstract
Hypoglycemia in the pediatric population tends to present in the newborn period or during metabolic crisis triggered by prolonged fasting and intercurrent illness. Current recommendations to investigate all children presenting with hypoglycemia for the first time are cumbersome and costly but necessary to identify those with serious conditions who predispose to hypoglycemia. We describe a practical and cost-effective method of evaluating children who present to the emergency department with previously undiagnosed hypoglycemia. Glucose and point-of-care (POC) beta-hydroxybutyrate levels should be measured on all children with a low screening POC glucose level, and a full history and physical examination will identify those requiring further investigation. This approach is suggested to identify patients with serious and life-threatening disease with the same fidelity as the currently recommended approach of performing a critical sample on all children with hypoglycemia. Our streamlined approach will reduce the cost to approximately 10% of the current approach per patient diagnosed with a serious underlying disease. Further, children without underlying hypoglycemia-predisposing disorders will be identified and discharged without unnecessary intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
209. Clinical and Molecular Characterization of Hyperinsulinism in Kabuki Syndrome.
- Author
-
Rosenfeld, Elizabeth, Mitteer, Lauren M, Boodhansingh, Kara, Sanders, Victoria R, McKnight, Heather, and Leon, Diva D De
- Subjects
HYPERINSULINISM ,DELAYED diagnosis ,CHILDREN'S hospitals ,SYNDROMES - Abstract
Context Kabuki syndrome (KS) is associated with congenital hyperinsulinism (HI). Objective To characterize the clinical and molecular features of HI in children with KS. Design Retrospective cohort study of children with KS and HI evaluated between 1998 and 2023. Setting The Congenital Hyperinsulinism Center of the Children's Hospital of Philadelphia. Patients Thirty-three children with KS and HI. Main Outcome Measure(s) HI presentation, treatment, course, and genotype. Results Hypoglycemia was recognized on the first day of life in 25 children (76%). Median age at HI diagnosis was 1.8 months (interquartile range [IQR], 0.6-6.1 months). Median age at KS diagnosis was 5 months (IQR, 2-14 months). Diagnosis of HI preceded KS diagnosis in 20 children (61%). Twenty-four children (73%) had a pathogenic variant in KMT2D , 5 children (15%) had a pathogenic variant in KDM6A , and 4 children (12%) had a clinical diagnosis of KS. Diazoxide trial was conducted in 25 children, 92% of whom were responsive. HI treatment was discontinued in 46% of the cohort at median age 2.8 years (IQR, 1.3-5.7 years). Conclusion Hypoglycemia was recognized at birth in most children with KS and HI, but HI diagnosis was often delayed. HI was effectively managed with diazoxide in most children. In contrast to prior reports, the frequency of variants in KMT2D and KDM6A were similar to their overall prevalence in individuals with KS. Children diagnosed with KS should undergo evaluation for HI, and, because KS features may not be recognized in infancy, KMT2D and KDM6A should be included in the genetic evaluation of HI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
210. Hipoglucemia inducida por un tumor de células no islóticas tratada con glucocorticoide y radioterapia: reporte de caso.
- Author
-
IBARRA-GARCÍA, STEPHANIA, CHÁVEZ-LÓPEZ, MARIANA, FERNÁNDEZ-OJEDA, FAYSI V., and CETINA-CANTO, JOSÉ A.
- Subjects
TREATMENT effectiveness ,PLEURAL tumors ,INSULIN ,ISLET cell tumor ,C-peptide ,DISEASE relapse ,GLUCOCORTICOIDS ,HYPOGLYCEMIA ,CELL receptors ,DISEASE complications - Abstract
Copyright of Revista Mexicana de Endocrinología, Metabolismo y Nutrición is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
211. The Impact of Cholecystectomy in Patients with Post-Bariatric Surgery Hypoglycemia.
- Author
-
Sardão, Daniel, Santos-Sousa, Hugo, Peleteiro, Bárbara, Resende, Fernando, Costa-Pinho, André, Preto, John, Lima-da-Costa, Eduardo, and Freitas, Paula
- Subjects
GLUCAGON-like peptide 1 ,HYPOGLYCEMIA ,BARIATRIC surgery ,CHOLECYSTECTOMY ,GLUCOSE metabolism ,BILE acids ,GASTRIC bypass - Abstract
Background: Metabolic surgery is the foremost treatment for obesity and its associated medical conditions. Nonetheless, post-bariatric hypoglycemia (PBH) emerges as a prevalent complication. PBH pathophysiology implicates heightened insulin and glucagon-like peptide 1 (GLP-1) levels, with bile acids (BA) contributing to GLP-1 release. A plausible association exists between cholecystectomy and PBH, which is attributed to alterations in BA metabolism and ensuing hormonal responses. The objective of this retrospective cohort study was to evaluate the impact of cholecystectomy on PBH pharmacological treatment, diagnostic timelines and metabolic parameters. Materials and methods: Patients diagnosed with PBH after bariatric surgery were evaluated based on their history of cholecystectomy. Demographic, anthropometric and clinical data were collected. Mixed meal tolerance tests (MMTT) results were compiled to assess metabolic responses. Results: Of the 131 patients with PBH included in the study, 29 had prior cholecystectomy. The time to PBH diagnosis was similar across groups. Patients with prior cholecystectomy required higher doses of acarbose (p = 0.046), compared to those without prior cholecystectomy. Additionally, MMTT revealed higher insulin (t = 60 min: p = 0.010 and t = 90 min: p = 0.034) and c-peptide levels (t = 60 min: p = 0.008) and greater glycemic variability in patients with prior cholecystectomy (p = 0.049), highlighting the impact of cholecystectomy on glucose metabolism. Conclusion: Our study offers novel insights into PBH pharmacotherapy, indicating that PBH patients with a history of cholecystectomy require elevated doses of acarbose for symptom control than PBH patients without such surgical history. Furthermore, our findings underscore the pivotal role of hyperinsulinism in PBH aetiology, emphasizing the significance of the BA-GLP-1-insulin axis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
212. Continuous Glucose Monitoring in Intensive Care Unit Patients with Diabetes: Insights and Outcomes from a Single‑center Study in India.
- Author
-
Jain, Sudeep, Bhalekar, Prashant, Sharma, Ankur, Sarkar, Nikita, Kamthe, Pooja, Bhake, Ragini, Purandare, Vedavati B., Tiwari, Shalbha, and Unnikrishnan, Ambika G.
- Subjects
TREATMENT of diabetes ,PEOPLE with diabetes ,GLYCOSYLATED hemoglobin ,GLYCEMIC control ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,BLOOD sugar ,CONTINUOUS glucose monitoring ,INTENSIVE care units ,MEDICAL records ,ACQUISITION of data ,QUALITY assurance ,PSYCHOSOCIAL factors ,HYPOGLYCEMIA - Abstract
Introduction: The use of continuous glucose monitoring (CGM) for in-hospital glucose control has been widely studied. However, its application in intensive care unit (ICU) settings is debatable owing to its perceived limitations. In ICU patients with diabetes, glycemic excursions, including frequent hypoglycemic episodes, are more prevalent. This retrospective study was undertaken to evaluate the utility of CGM in the management of diabetes patients admitted to the ICU. Methods: We collected data of patients with diabetes mellitus who were admitted to the ICU at our institution and were advised CGM by the intensivist. Aretrospective analysis was conducted, examining demographic, clinical, and laboratory data, along with glucose meter readings and CGM data. The results are presented as numbers, percentages, or median values, as appropriate. Results: Out of 65 patients in the ICU, the median values of percentage time in range, time below range, and time above range were 59%, 2%, and 36%, respectively. The median HbA1 C and capillary glucose on admission were 8.8% and 246 mg/dl, respectively. During the ICU stay, the CGM derived average glucose level was 167 mg/dl (percent coefficient of variation [%CV] =25.96) and the glucose management indicator was 7%. In total, 65 episodes of hypoglycemia were detected, all confirmed by capillary glucose tests. A total of 27 patients experienced hypoglycemia, of which 12 had nocturnal hypoglycemia. Conclusion: The use of CGM in the ICU improved glycemic control and helped to detect hypoglycemia, particularly nocturnal with acceptably low glycemic variability as measured by percentage CV. Further studies are required to corroborate and confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
213. Perioperatives Vorgehen bei Patientinnen und Patienten mit Diabetes.
- Author
-
Hüppe, T.
- Subjects
SURGERY ,PATIENTS ,CONTINUING medical education ,INSULIN ,INTRAVENOUS therapy ,PERIOPERATIVE care ,HYPOGLYCEMIA ,SUBCUTANEOUS injections ,CRITICAL care medicine - Abstract
Copyright of Anaesthesiologie & Intensivmedizin is the property of DGAI e.V. - Deutsche Gesellschaft fur Anasthesiologie und Intensivmedizin e.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
214. Nocturnal Glucose Profile According to Timing of Dinner Rapid Insulin and Basal and Rapid Insulin Type: An Insulclock ® Connected Insulin Cap-Based Real-World Study.
- Author
-
Gómez-Peralta, Fernando, Valledor, Xoan, Abreu, Cristina, Fernández-Rubio, Elsa, Cotovad, Laura, Pujante, Pedro, Azriel, Sharona, Pérez-González, Jesús, Vallejo, Alba, Ruiz-Valdepeñas, Luis, and Corcoy, Rosa
- Subjects
CONTINUOUS glucose monitoring ,INSULIN derivatives ,TYPE 1 diabetes ,INSULIN therapy ,HYPOGLYCEMIA - Abstract
Background: A study to assess the glucose levels of people with type 1 diabetes (T1D) overnight, based on the insulin type and timing. Methods: A real-world, retrospective study of T1D, using multiple daily insulin injections. Continuous glucose monitoring and insulin injection data were collected for ten hours after dinner using the Insulclock
® connected cap. Meal events were identified using the ROC detection methodology. The timing of the rapid insulin, second injections, and the type of insulin analogs used, were evaluated. Results: The nocturnal profiles (n = 775, 49 subjects) were analyzed. A higher glucose AUC of over 180 mg/dL was observed in subjects with delayed injections (number; %; mg/dL × h): −45–15 min (n = 136; 17.5%, 175.9 ± 271.0); −15–0 min (n = 231; 29.8%, 164.0 ± 2 37.1); 0 + 45 min (n = 408; 52.6%, 203.6 ± 260.9), (p = 0.049). The use of ultrarapid insulin (FiAsp® ) (URI) vs. rapid insulin (RI) analogs was associated with less hypoglycemia events (7.1 vs. 13.6%; p = 0.005) and TBR70 (1.7 ± 6.9 vs. 4.6 ± 13.9%; p = 0.003). Users of glargine U300 vs. degludec had a higher TIR (70.7 vs. 58.5%) (adjusted R-squared: 0.22, p < 0.001). The use of a correction injection (n = 144, 18.6%) was associated with a higher number of hypoglycemia events (18.1 vs. 9.5%; p = 0.003), TBR70 (5.5 ± 14.2 vs. 3.0 ± 11.1%; p = 0.003), a glucose AUC of over 180 mg/dL (226.1 ± 257.8 vs. 178.0 ± 255.3 mg/dL × h; p = 0.001), and a lower TIR (56.0 ± 27.4 vs. 62.7 ± 29.6 mg/dL × h; p = 0.004). Conclusion: The dinner rapid insulin timing, insulin type, and the use of correction injections affect the nocturnal glucose profile in T1D. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
215. Naming hypoglycemia: a narrative tool for young people with type 1 diabetes and their families.
- Author
-
do Rosário, Francisco Sobral, Soares, Marta, Mesquita, Filipe, and Raposo, João Filipe
- Abstract
Objective: Hypoglycemia constitutes a communication barrier between youth with type 1 diabetes, their family members and health professionals. A narrative tool may contribute to a more effective communication. Methods: Semi-structured interviews with six open-ended questions using narrative techniques collect and analyze (thematic and comparative analysis) different ways of "naming" the lived experience of hypoglycemia. Results: 103 participants, 40 with type 1 Diabetes aged 10–18 years (17 female), 63 relatives (40 female). Group 1 (G1), 10–14 years old (n = 21), Group 2 (G2), 15–18 years old (n = 19), Group 3 (G3) relatives, 30–59 years old. G3 was divided, G3.1: female (n = 42) and G3.2: male (n = 21). G1 and G2 presents greater attention to symptoms. G1 refers a greater need for help, G2 emphasizes autonomy. G2 and G3 describes better the medical protocol. G1 and G2 refer more topics such as "discomfort", "frustration", "obligation", "difficulty in verbalizing", G3 refers to "gilt", "fear" and "responsibility". G3.1 refer more "symptoms", "responsibility", "fault", "incapacity". Conclusions: A narrative tool enhances the singularity of a common experience, proving itself useful to adolescents, relatives, and healthcare professionals. Practice implications: In addition to gathering information that is usually acquired empirically, a narrative tool exposes knowledge gaps and may allow implementing intervention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
216. Predictors of the effectiveness of isCGM usage in adults with type 1 diabetes mellitus: post-hoc analysis of the ISCHIA study.
- Abstract
Aim: The Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus (ISCHIA) study was a randomized, crossover trial that reported the decrease in time below range (TBR) by the use of intermittent-scanning continuous glucose monitoring (isCGM) combined with structured education in adults with type 1 diabetes (T1D) treated by multiple daily injections. The participants were instructed to perform frequent scanning of the isCGM sensor (10 times a day or more) and ingest sugar when impending hypoglycemia is suspected by tracking the sensor glucose levels and the trend arrow. We conducted post-hoc analysis to identify factors affecting difference in TBR (∆TBR), in time in range (∆TIR), and in time above range (∆TAR). Participants and methods: Data from 93 participants who completed the ISCHIA study were used. Multiple regression analyses were performed to identify factors affecting CGM metrics. Results: Pearson's correlation analysis showed the negative association between log-transformed scan frequency and with ∆TBR (r = − 0.255, P = 0.015), while there was no significant association of log-transformed scan frequency with ∆TIR (r = 0.172, P = 0.102) and ∆TAR (r = 0.032, P = 0.761), respectively. The log-transformed scan frequency was an independent predictor of ∆TBR (Beta = − 7.712, P = 0.022), but not of ∆TIR(Beta = 7.203, P = 0.091) and of ∆TAR (Beta = 0.514, P = 0.925). Conclusions: Our findings suggest that more frequent scanning of isCGM may be beneficial to reduce TBR in T1D adults. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
217. Mild Aromatic L-Amino Acid Decarboxylase Deficiency Causing Hypoketotic Hypoglycemia in a 4-year-old Girl
- Author
-
Merve Yoldaş Çelik, Ebru Canda, Havva Yazıcı, Fehime Erdem, Ayşe Yüksel Yanbolu, Ayça Aykut, Asude Durmaz, Ahmet Anık, Sema Kalkan Uçar, and Mahmut Çoker
- Subjects
aromatic l-amino acid decarboxylase deficiency ,aadc deficiency ,hypoglycemia ,neurotransmitter deficiency ,Pediatrics ,RJ1-570 ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Aromatic L-amino acid decarboxylase (AADC) deficiency is a disease in which neurological findings are dominant due to deficiencies in neurotransmitter synthesis. Hypoglycemia caused by autonomic dysfunction is one of the symptoms that may be encountered. Here we report a case of mild AADC deficiency presenting with hypoglycemia without any neurological signs. A 4-year-old girl presented with recurrent hypoglycemia. Her growth and development were normal. Plasma insulin and cortisol values were normal in the sample at the time of hypoglycemia. C8: 1-Carnitine elevation was detected in the acylcarnitine profile. A clinical exome panel was performed with the suggestion of a fatty acid oxidation defect. However, a homozygous variant in the DDC gene was detected. Furthermore, cerebrospinal fluid neurotransmitter analysis revealed low 5-hydroxyindolacetic acid and homovanillic acid and high 3-O-methyl-dopa and methyltetrahydrofolate (5 MTHF) consistent with AADC deficiency. Plasma AADC enzyme activity was low. The episodes of hypoglycemia were treated with uncooked cornstarch. This case suggests that AADC deficiency should be considered in some patients with hypoglycemia.
- Published
- 2024
- Full Text
- View/download PDF
218. Islet transplantation in Korea
- Author
-
Joonyub Lee and Kun‐Ho Yoon
- Subjects
diabetes mellitus Type 1 ,Hypoglycemia ,Islets of Langerhans transplantation ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Type 1 diabetes mellitus is characterized by absolute insulin deficiency, which requires life‐long insulin replacement. Exogenous multiple‐daily insulin injections are most commonly prescribed for patients with type 1 diabetes mellitus. However, exogenous insulin supply often fails to cope with real‐time changing life‐log variables, such as activity, diet and stress, which results in recurrent hypo‐ and hyperglycemia in patients with type 1 diabetes mellitus. Islet transplantation is an ideal method to treat patients with type 1 diabetes mellitus, as it can restore the endogenous capacity of glucose‐stimulated insulin secretion. However, due to donor scarcity and technical barriers, only a limited number of islet transplantations have been carried out in Asia, including South Korea. Since 2013, our center has carried out two allogenic islet transplantations, with one case leading to near total insulin independence after one‐to‐one islet transplantation. Although the other patient failed to restore endogenous insulin production, there was a remarkable improvement in hypoglycemia. We speculate that islet transplantation remains an important and ideal treatment option for patients with type 1 diabetes mellitus who suffer from recurrent severe hypoglycemia.
- Published
- 2024
- Full Text
- View/download PDF
219. Risk factors for neonatal hypoglycemia: a meta-analysis
- Author
-
Dandan Wang, Xuchen Zhou, Juan Ning, Fen He, Junhui Shi, and Xuefeng Jin
- Subjects
Neonatal ,Hypoglycemia ,Risk factors ,Meta-analysis ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Objective This Study aims to investigate the risk factors of hypoglycemia in neonates through meta-analysis. Method PubMed, Embase, Cochrane library, and Web of science databases were searched for case-control studies on risk factors for neonatal hypoglycemia. The search was done up to 1st October 2023 and Stata 15.0 was used for data analysis. Results A total of 12 published studies were included, including 991 neonates in the hypoglycemic group and 4388 neonates in the non-hypoglycemic group. Meta-analysis results suggested caesarean section [OR = 1.90 95%CI (1.23, 2.92)], small gestational age[OR = 2.88, 95%CI (1.59, 5.20)], gestational diabetes [OR = 1.65, 95%CI (1.11, 2.46)], gestational hypertension[OR = 2,79, 95%CI (1.78, 4.35)] and respiratory distress syndrome[OR = 5.33, 95%CI (2.22, 12.84)] were risk factors for neonatal hypoglycemia. Conclusion Based on the current study, we found that caesarean section, small gestational age, gestational diabetes, gestational hypertension, respiratory distress syndrome are risk factors for neonatal hypoglycemia. PROSPERO registration number CRD42023472974.
- Published
- 2024
- Full Text
- View/download PDF
220. Doege-Potter syndrome due to a solitary fibrous tumor of the pleura: a case report
- Author
-
Juan Estrada-Maya, Juan Sebastián Montejo, Katerin Dayana Báez López, and Juan Carlos Garzón
- Subjects
Solitary fibrous tumor ,Hypoglycemia ,Insulin-like growth factor II ,Doege-Potter syndrome ,Paraneoplastic syndrome ,Medicine - Abstract
Abstract Background Doege-Potter syndrome is a rare paraneoplastic phenomenon associated with solitary fibrous tumors of the pleura (SFTPs). It is characterized by the presence of severe, sustained, and treatment-refractory hypoglycemia. Hypoglycaemia, which may be the sole symptom at disease onset, is mediated by the secretion of high-molecular-weight insulin-like growth factor (IGF-2). Most tumors exhibit benign behavior, with a 100% survival rate at 5 years. However, 10% of these tumors may display aggressive behavior with local or metastatic recurrence. We present a clinical case of a patient with a benign solitary fibrous tumor of the pleura who presented with symptomatic hypoglycemia and required pulmonary and pleural surgical resection to control the paraneoplastic phenomenon. Case presentation A Hispanic 46-year-old man presented with a 15-day history of transient alterations in consciousness worsened by fasting. The relevant medical history included obstructive sleep apnea treated with continuous positive air pressure (CPAP) and previous smoking. In-hospital studies revealed noninsulinemic hypoglycemia and a benign SFTP. Complete surgical resection was performed while the patient received dextrose fluids and corticosteroids perioperatively for hypoglycemia. Subsequently, the hypoglycemia resolved, and the patient was followed-up without disease recurrence. Conclusion Doege-Potter syndrome is challenging to recognize. However, effective treatment can be achieved with a high survival rate. Raising awareness among healthcare professionals about the recognition of this paraneoplasic syndrome patients will improve diagnostic suspicion, biochemical confirmation, the development of diagnostic and therapeutic guidelines, and the creation of predictive indices for aggressive presentations requiring closer monitoring.
- Published
- 2024
- Full Text
- View/download PDF
221. Clinical case of diagnosis and treatment of insulinoma
- Author
-
Natalia A. Nikitina, Artyom V. Snitsar, Marina V. Kuandykova, Konstantin A. Pokrovsky, Sergey A. Yerin, Vyacheslav A. Shibitov, Natalia V. Brevnova, and Nina A. Petunina
- Subjects
insulinoma ,hypoglycemia ,hypoglycemis syndrome ,hyperinsulinism ,neuroendocrine pancreatic tumor ,Internal medicine ,RC31-1245 - Abstract
Insulinoma is a rare neuroendocrine pancreatic tumor that typically produces excessive amout of hormone insulin. The main clinical manifestations of insulinoma are episodes of hypoglycemia. The low prevalence of the disease, the complexity of clinical and laboratory diagnosis, as well as the difficulty of topical diagnosis, low awareness physicians of related specialties, often cause untimely diagnosis of the disease, which worsens patients life-quality and prognosis. This article presents a clinical case of diagnosis and treatment of insulinoma in a non-specialized hospital. The article describes the methods of laboratory and topical diagnostics, as well as treatment tactics of patients with this disease.
- Published
- 2024
- Full Text
- View/download PDF
222. Multiple Liver Metastases in Malignant Insulinoma: A Case Report
- Author
-
LIAO Jinhao, GAO Yuting, WANG Xiang, WANG Zhiwei, XU Qiang, ZHAO Yuxing, CHI Yue, MAO Jiangfeng, and YANG Hongbo
- Subjects
hypoglycemia ,malignant insulinoma ,multidisciplinary treatment ,Medicine - Abstract
Malignant insulinoma is a kind of rare and challenging neuroendocrine tumor. It is often accompanied by distant metastasis, among which liver metastasis is most common, and the prognosis is often non-promising. In this paper, we report a case of multiple liver metastases from malignant insulinoma. The patient, a 70-year-old male, was admitted to the hospital due to "episodic consciousness disorder for more than four months." Blood glucose monitoring revealed recurrent hypoglycemia in the early morning, after meals, and at night. Pancreatic perfusion CT and dynamic enhanced MRI of the liver revealed a mass in the uncinate process of the pancreatic head and multiple liver metastases. Percutaneous liver biopsy confirmed the diagnosis of insulinoma. After multidisciplinary discussions, hepatic artery embolization and radiofrequency ablation were performed in stages, in combination with everolimus treatment. Thereafter, the enhanced CT demonstrated that some liver metastases shrank. The patient had regular meals, and the blood sugar gradually increased and remained normal thereafter. This article discusses this case's clinical characteristics and multidisciplinary collaborative diagnosis and treatment, aiming to provide experience for the comprehensive clinical diagnosis and treatment of malignant insulinoma patients.
- Published
- 2024
- Full Text
- View/download PDF
223. Effect of recurrent severe insulin-induced hypoglycemia on the cognitive function and brain oxidative status in the rats
- Author
-
Mahvash Nikpendar, Mohammad Javanbakht, Hamidreza Moosavian, Sepideh Sajjadi, Yalda Nilipour, Toktam Moosavian, and Mahsa Fazli
- Subjects
Insulin ,Hypoglycemia ,Cognitive function ,Hippocampus ,Oxidative stress ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Episodes of recurrent or severe hypoglycemia can occur in patients with diabetes mellitus, insulinoma, neonatal hypoglycemia, and medication errors. However, little is known about the short-term and long-term effects of repeated episodes of acute severe hypoglycemia on the brain, particularly in relation to hippocampal damage and cognitive dysfunction. Methods Thirty-six wistar rats were randomly assigned to either the experimental or control group. The rats were exposed to severe hypoglycemia, and assessments were conducted to evaluate oxidative stress in brain tissue, cognitive function using the Morris water maze test, as well as histopathology and immunohistochemistry studies. The clinical and histopathological evaluations were conducted in the short-term and long-term. Results The mortality rate attributed to hypoglycemia was 34%, occurring either during hypoglycemia or within 24 h after induction. Out of the 14 rats monitored for 7 to 90 days following severe/recurrent hypoglycemia, all exhibited clinical symptoms, which mostly resolved within three days after the last hypoglycemic episode, except for three rats. Despite the decrease in catalase activity in the brain, the total antioxidant capacity following severe insulin-induced hypoglycemia increased. The histopathology findings revealed that the severity of the hippocampal damage was higher compared to the brain cortex 90 days after hypoglycemia. Memory impairments with neuron loss particularly pronounced in the dentate gyrus region of the hippocampus were observed in the rats with severe hypoglycemia. Additionally, there was an increase in reactive astrocytes indicated by GFAP immunoreactivity in the brain cortex and hippocampus. Conclusion Recurrent episodes of severe hypoglycemia can lead to high mortality rates, memory impairments, and severe histopathological changes in the brain. While many histopathological and clinical changes improved after three months, it seems that the vulnerability of the hippocampus and the development of sustained changes in the hippocampus were greater and more severe compared to the brain cortex following severe and recurrent hypoglycemia. Furthermore, it does not appear that oxidative stress plays a central role in neuronal damage following severe insulin-induced hypoglycemia. Further research is necessary to assess the consequences of repeated hypoglycemic episodes on sustained damage across various brain regions.
- Published
- 2024
- Full Text
- View/download PDF
224. Hyponatremia as acute adrenal insufficiency in patients with type 1 diabetes mellitus and kidney transplantation cause end-stage chronic kidney disease
- Author
-
I. S. Khagabanova, O. K. Vikulova, M. S. Shamkhalova, E. A. Pigarova, S. A. Martinov, and V. Y. Kalashnikov
- Subjects
chronic adrenal insufficiency ,type 1 diabetes mellitus ,hyponatremia ,hypoglycemia ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Diabetes mellitus type 1 (DM1) and chronic adrenal insufficiency (CAF) are among the most common autoimmune endocrine diseases that develop both isolated and in combination with each other and with other diseases of autoimmune origin, as part of various syndromes. At the same time, type 1 diabetes is quite often the first component of a systemic autoimmune lesion and acts as a predictor of the development of congenital disorder, which, in turn, against the background of type 1 diabetes, acquires a mild, sometimes atypical course, which complicates the diagnosis and prescription of therapy. The clinical case describes a patient with type 1 diabetes and end-stage chronic kidney disease (CKD), kidney allotransplantation (ART), who was on triple immunosuppressive therapy, who developed CHN, which was manifested by severe hyponatremia and the occurrence of frequent hypoglycemic conditions.
- Published
- 2024
- Full Text
- View/download PDF
225. Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia
- Author
-
Luting Zhou, Yang Liu, Teng Xu, Lei Dong, Xiaoqun Yang, and Chaofu Wang
- Subjects
Solitary fibrous tumor ,STAT6 ,NAB2-STAT6 ,Hypoglycemia ,IGF2 ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor that mostly involves the pleura and infrequently involves extra-pleural sites. De novo SFT of the kidney is uncommon, and malignant SFT is extremely rare. Case presentation We report a case of a 51-year-old man with a large malignant SFT in the left kidney. Pathological examination confirmed the diagnosis of SFT based on typical morphology, nuclear STAT6 expression, and NAB2-STAT6 gene fusion. The malignant subtype was determined by a large tumor size (≥ 15 cm) and high mitotic counts (8/10 high-power fields). KRAS mutation was identified by DNA sequencing. Insulin-like growth factor 2 (IGF2) was diffusely and strongly expressed in tumor cells, however, hypoglycemia was not observed. Hyperglycemia and high adrenocorticotropic hormone (ACTH) concentration were observed one month after surgery. Hormone measurements revealed normal blood cortisol and aldosterone levels, and increased urinary free cortisol level. A pituitary microadenoma was identified using brain magnetic resonance imaging, which may be responsible for the promotion of hyperglycemia. Conclusions We report a case of renal malignant SFT with a KRAS mutation, which was previously unreported in SFT and may be associated with its malignant behavior. Additionally, we emphasize that malignant SFT commonly causes severe hypoglycemia due to the production of IGF2. However, this effect may be masked by the presence of other lesions that promote hyperglycemia. Therefore, when encountering a malignant SFT with diffuse and strong IGF2 expression and without hypoglycemia, other lesions promoting hyperglycemia need to be ruled out.
- Published
- 2024
- Full Text
- View/download PDF
226. Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes
- Author
-
Patricia Medici Dualib, Sergio Atala Dib, Gustavo Akerman Augusto, Ana Cristina Truzzi, Mauricio Aguiar de Paula, and Rosângela Roginski Réa
- Subjects
Diabetes mellitus, type 1 ,Insulin glargine ,HbA1c ,Glycemic profile ,Hypoglycemia ,Dawn phenomenon ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Low adherence to the number of insulin injections and glycemic variability are among the challenges of insulin therapy in type 1 diabetes (T1D). The TOP1 study investigated the effect of switching from twice-daily (BID) basal insulin to once daily (OD) insulin glargine 300 U/mL (Gla-300) on glycemic control and quality of life. Methods In this 28-week, phase 4 trial, people with T1D aged ≥ 18 years, who were treated with BID basal insulin in combination with prandial rapid-acting insulin for at least 1 year, and had HbA1c between 7.5% and 10.0%, were switched to Gla-300 OD as basal insulin. The present study aimed to evaluate the impact of this change on HbA1c, glycemic profile, treatment satisfaction and safety. The change in HbA1c from baseline to Week 24 was the primary endpoint. Results One hundred and twenty-three people with T1D (mean age 37 ± 11 years; 54.5% female) were studied. The disease duration was 20.0 ± 9.8 years, baseline HbA1c and fasting plasma glucose (FPG) were 8.6 ± 0.7% and 201 ± 80.3 mg/dL, respectively. After switching from BID to OD insulin regimen, no significant change in HbA1c was observed from baseline to Week 24 (p = 0.873). There were significant reductions in fasting self-monitoring blood glucose (SMBG) from baseline to Week 24 (175 ± 42 vs. 156 ± 38 mg/dL; p
- Published
- 2024
- Full Text
- View/download PDF
227. Progressive Malignant Insulinoma with Multiple Liver Metastases: A Case Report
- Author
-
Zahra Davoudi, Shahriar Nikpour, Farahnaz Bidari Zerehpoosh, Sina Homaee, Mohammad Farzad Nazari, Farnaz Saberian, and Hamed Borhany
- Subjects
metastasis ,malignant insulinoma ,hypoglycemia ,Medicine (General) ,R5-920 - Abstract
Background: Insulin-secreting tumors are the most common hormone-producing neoplasm of the gastrointestinal tract. Only 10 percent of overall cases of insulinoma have malignant variants, which have a poor prognosis. Cases Report: The present study reports an unusual case of pancreatic neuroendocrine tumor associated with hypoglycemia and liver metastasis as the initial presentation followed a rapidly progressive clinical course. A few cases of malignant insulinoma were reported with favorable responses in the literature. This research presents a patient with resistant malignant insulinoma who could not undergo an operation and received treatment with somatostatin analogs (S.S.A.), Peptide Receptor Radionuclide Therapy (PRRT), and other supportive care that was inappropriate. Conclusion: Early diagnosis and extensive treatment are auspicious for improving the prognosis of malignant insulinoma, and proper treatment with medications would increase the quality of life of patients. Nevertheless, unfortunately, late patient referrals, socioeconomic conditions, and being infected with Covid-19 disease resulted in death.
- Published
- 2024
- Full Text
- View/download PDF
228. The end of obesity?
- Author
-
Wilson, Clare
- Subjects
- *
WEIGHT loss , *OBESITY , *ANTIOBESITY agents , *HYPOGLYCEMIA , *WEIGHT gain , *YOUNG adults - Abstract
The impact of this new class of medicines could be unprecedented - potentially bringing to an end the world's growing obesity epidemic. Features THERE are TikTok hashtags with millions of followers, endless column inches over celebrities' waistlines and streams of media coverage when trial results come out. Drugs like Wegovy dampen activity in these neurons, which helps explain why people avoid the normal hunger response to weight loss if they are taking these medicines, says Schwartz. The funding question is mired in longstanding societal judgements about fatness and the use of weight-loss drugs, in a way that doesn't happen for people who need other lifelong medication, says Paul Gately at Leeds Beckett University in the UK, who runs an obesity clinic. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
229. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
- Author
-
Klonoff, David C, Wang, Jing, Rodbard, David, Kohn, Michael A, Li, Chengdong, Liepmann, Dorian, Kerr, David, Ahn, David, Peters, Anne L, Umpierrez, Guillermo E, Seley, Jane Jeffrie, Xu, Nicole Y, Nguyen, Kevin T, Simonson, Gregg, Agus, Michael SD, Al-Sofiani, Mohammed E, Armaiz-Pena, Gustavo, Bailey, Timothy S, Basu, Ananda, Battelino, Tadej, Bekele, Sewagegn Yeshiwas, Benhamou, Pierre-Yves, Bequette, B Wayne, Blevins, Thomas, Breton, Marc D, Castle, Jessica R, Chase, James Geoffrey, Chen, Kong Y, Choudhary, Pratik, Clements, Mark A, Close, Kelly L, Cook, Curtiss B, Danne, Thomas, Doyle, Francis J, Drincic, Angela, Dungan, Kathleen M, Edelman, Steven V, Ejskjaer, Niels, Espinoza, Juan C, Fleming, G Alexander, Forlenza, Gregory P, Freckmann, Guido, Galindo, Rodolfo J, Gomez, Ana Maria, Gutow, Hanna A, Heinemann, Lutz, Hirsch, Irl B, Hoang, Thanh D, Hovorka, Roman, Jendle, Johan H, Ji, Linong, Joshi, Shashank R, Joubert, Michael, Koliwad, Suneil K, Lal, Rayhan A, Lansang, M Cecilia, Lee, Wei-An, Leelarathna, Lalantha, Leiter, Lawrence A, Lind, Marcus, Litchman, Michelle L, Mader, Julia K, Mahoney, Katherine M, Mankovsky, Boris, Masharani, Umesh, Mathioudakis, Nestoras N, Mayorov, Alexander, Messler, Jordan, Miller, Joshua D, Mohan, Viswanathan, Nichols, James H, Nørgaard, Kirsten, O’Neal, David N, Pasquel, Francisco J, Philis-Tsimikas, Athena, Pieber, Thomas, Phillip, Moshe, Polonsky, William H, Pop-Busui, Rodica, Rayman, Gerry, Rhee, Eun-Jung, Russell, Steven J, Shah, Viral N, Sherr, Jennifer L, Sode, Koji, Spanakis, Elias K, Wake, Deborah J, Waki, Kayo, Wallia, Amisha, Weinberg, Melissa E, Wolpert, Howard, Wright, Eugene E, Zilbermint, Mihail, and Kovatchev, Boris
- Subjects
Biomedical and Clinical Sciences ,Nutrition and Dietetics ,Diabetes ,Adult ,Humans ,Blood Glucose ,Blood Glucose Self-Monitoring ,Hypoglycemia ,Hyperglycemia ,Glucose ,ambulatory glucose profile ,composite metric ,continuous glucose monitor ,diabetes ,glycemia risk index ,hyperglycemia ,hypoglycemia ,time in range ,Nutrition and dietetics - Abstract
BackgroundA composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data.MethodsWe assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low-glucose and low-glucose hypoglycemia; very high-glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation.ResultsThe analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals.ConclusionThe GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.
- Published
- 2023
230. Effects of Urocortin 2 Gene Transfer on Glucose Disposal in Insulin-Resistant db/db Mice on Metformin.
- Author
-
Gao, Mei, Giamouridis, Dimosthenis, Lai, N, Guo, Tracy, and Hammond, H
- Subjects
adeno-associated virus type 8 ,gene therapy ,insulin sensitivity ,metformin ,Mice ,Animals ,Glucose ,Insulin ,Metformin ,Urocortins ,Adenylate Kinase ,Alanine Transaminase ,Hypoglycemia - Abstract
The study was designed to determine whether urocortin 2 (Ucn2) gene transfer is as safe and effective as metformin in insulin-resistant mice. Four groups of insulin-resistant db/db mice and a nondiabetic group were studied: (1) metformin; (2) Ucn2 gene transfer; (3) metformin + Ucn2 gene transfer; (4) saline; and (5) nondiabetic mice. After completion of the 15-week protocol, glucose disposal was quantified, safety assessed, and gene expression documented. Ucn2 gene transfer was superior to metformin, providing reductions in fasting glucose and glycated hemoglobin and enhanced glucose tolerance. The combination of metformin + Ucn2 gene transfer provided no better glucose control than Ucn2 gene transfer alone and was not associated with hypoglycemia. Metformin alone, Ucn2 gene transfer alone, and metformin + Ucn2 gene transfer together reduced fatty infiltration of the liver. Serum alanine transaminase concentration was elevated in all db/db groups (vs. nondiabetic controls), but the metformin + Ucn2 gene transfer combined group had the lowest alanine transaminase levels. No group differences in fibrosis were detected. In a hepatoma cell line, activation of AMP kinase showed a rank order of combined metformin + Ucn2 peptide > Ucn2 peptide > metformin. We conclude (1) The combination of metformin + Ucn2 gene transfer does not result in hypoglycemia. (2) Ucn2 gene transfer alone provides superior glucose disposal versus metformin alone. (3) The combination of Ucn2 gene transfer and metformin is safe and has additive effects in reducing serum alanine transaminase concentration, activating AMP kinase activity, and increasing Ucn2 expression, but is no more efficacious than Ucn2 gene transfer alone in reducing hyperglycemia. These data indicate that Ucn2 gene transfer is more effective than metformin in the db/db model of insulin resistance and combined treatment with metformin + Ucn2 gene transfer appears to have favorable effects on liver function and Ucn2 expression.
- Published
- 2023
231. Hypoglycemia After Ingestion of 'Street Valium' Containing Glyburide, Alcohol, and Cocaine
- Author
-
Amanda L. McKenna, MD, Jessica R. Wilson, MD, Adrian G. Dumitrascu, MD, Shon E. Meek, MD, PhD, and Ana-Maria Chindris, MD
- Subjects
benzodiazepine ,drug abuse ,hypoglycemia ,sulfonylurea ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background/Objective: Because of their similar appearance and inexpensive cost, sulfonylureas can cause hypoglycemia when substituted for benzodiazepines by the illicit drug market. We present a patient who developed hypoglycemia after ingestion of what she thought to be Valium; work-up revealed sulfonylurea exposure. Case Report: A 33-year-old patient was brought to the hospital after being found unresponsive by paramedics with a reported venous blood glucose level of 18 mg/dL (reference range, 70-140 mg/dL). This prompted treatment with 12.5 g of dextrose administered intravenously. At the hospital, the venous blood glucose level was 15 mg/dL resulting in intravenous dextrose infusion initiation. Once stable, the patient endorsed a medical history of substance use disorder and anxiety. She reported ingesting 2 blue pills given to her by a friend as Valium for her anxiety. Laboratory values showed an elevated insulin level of 47.4 mIU/mL (2.6-24.9), an elevated C-peptide level of 5.4 ng/mL (1.1-4.4), and a glucose level of 44 mg/dL (>70 mg/dL). The patient underwent a 72-hour fasting test. Blood hypoglycemia agent screening showed positive results for glyburide (>5 ng/mL). The patient was discharged home in stable condition. Discussion: There are approximately 2 to 5 case reports of hypoglycemia among persons taking illicit drugs containing sulfonylureas. Laboratory values consistent with the use of a hypoglycemic agent include elevated insulin and C-peptide levels, a low glucose level, and positive results for hypoglycemia agent screening. Conclusion: Sulfonylurea-induced hypoglycemia may lead to clinical sedation, mimicking the effects of benzodiazepines. Sulfonylurea substitution or drug contamination should be suspected when severe hypoglycemia is diagnosed in unresponsive patients suspected of taking illicit drugs.
- Published
- 2024
- Full Text
- View/download PDF
232. Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy
- Author
-
Yadong Ni, Xianglong Wu, Wenhui Yao, Yuna Zhang, Jie Chen, and Xuansheng Ding
- Subjects
Hypoglycemia ,diabetes management ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Context The global prevalence of type 2 diabetes mellitus (T2DM) has increased significantly in recent decades. Despite numerous studies and systematic reviews, there is a gap in comprehensive and up-to-date evaluations in this rapidly evolving field.Objective This review provides a comprehensive and current overview of the efficacy of Traditional Chinese Medicine (TCM) in treating T2DM.Methods A systematic review was conducted using PubMed, Web of Science, Wanfang Data, CNKI, and Medline databases, with a search timeframe extending up to November 2023. The search strategy involved a combination of subject terms and free words in English, including ‘Diabetes,’ ‘Traditional Chinese Medicine,’ ‘TCM,’ ‘Hypoglycemic Effect,’ ‘Clinical Trial,’ and ‘Randomized Controlled Trial.’ The studies were rigorously screened by two investigators, with a third investigator reviewing and approving the final selection based on inclusion and exclusion criteria.Results A total of 108 relevant papers were systematically reviewed. The findings suggest that TCMs not only demonstrate clinical efficacy comparable to existing Western medications in managing hypoglycemia but also offer fewer adverse effects and a multitarget therapeutic approach. Five main biological mechanisms through which TCM treats diabetes were identified: improving glucose transport and utilization, improving glycogen metabolism, promoting GLP-1 release, protecting pancreatic islets from damage, and improving intestinal flora.Conclusions TCM has demonstrated significant protective effects against diabetes and presents a viable option for the prevention and treatment of T2DM. These findings support the further exploration and integration of TCM into broader diabetes management strategies.
- Published
- 2024
- Full Text
- View/download PDF
233. A Patient with a History of Traumatic Brain Injury and Fever
- Author
-
An, Lucia, Ferber, Christopher J., Siddiqui, Hanna, Kamzan, Audrey, editor, Kulkarni, Deepa, editor, and Newcomer, Charles A., editor
- Published
- 2024
- Full Text
- View/download PDF
234. Transitioning Adolescents and Young Adults with Type 1 Diabetes to Adulthood
- Author
-
D’Amico, Rachel, Buschur, Elizabeth O., Kuo, Alice A, editor, Pilapil, Mariecel, editor, DeLaet, David E., editor, Peacock, Cynthia, editor, and Sharma, Niraj, editor
- Published
- 2024
- Full Text
- View/download PDF
235. Principles of Care in the Diabetic Surgical Patient
- Author
-
Khazai, Natasha, Hamdy, Osama, Veves, Aristidis, Series Editor, Giurini, John M., editor, and Schermerhorn, Marc L., editor
- Published
- 2024
- Full Text
- View/download PDF
236. Post-chemotherapy Nausea and Vomiting, Hypoglycemia
- Author
-
Aydin, Ani, Joseph, Daniel, Joseph, Melissa, Aydin, Ani, Joseph, Daniel, and Joseph, Melissa
- Published
- 2024
- Full Text
- View/download PDF
237. Diabetes
- Author
-
Pandya, Naushira, Patel, Meenakshi, Wasserman, Michael R., Section editor, Cesari, Matteo, Section editor, Wasserman, Michael R., editor, Bakerjian, Debra, editor, Linnebur, Sunny, editor, Brangman, Sharon, editor, Cesari, Matteo, editor, and Rosen, Sonja, editor
- Published
- 2024
- Full Text
- View/download PDF
238. Insulin
- Author
-
Paavola, Chad D., De Felippis, Michael R., Allen, David P., Garg, Ashish, Sabatowski, James L., Juneja, Rattan, Baldwin, D. Bruce, Crommelin, Daan J. A., editor, Sindelar, Robert D., editor, and Meibohm, Bernd, editor
- Published
- 2024
- Full Text
- View/download PDF
239. The Next Frontier in Blood Sugar Management: GLP-1 medications, new glucose trackers, and calls for stronger substantiation are fueling this white-hot category of health products.
- Author
-
Montemarano, Mike
- Subjects
BLOOD sugar ,PEOPLE with diabetes ,HEALTH products ,HYPOGLYCEMIA ,GLUCOSE ,MEDICATION therapy management ,NUTRITION education ,HEALTH literacy - Abstract
This article discusses the growing market for blood sugar management supplements and products. It highlights various products that contain ingredients such as mulberry, lemon flavonoid, cinnamon bark extracts, and antioxidants, which are meant to be taken before carb-heavy meals. The article also mentions concerns raised by the U.S. Federal Trade Commission (FTC) about influencer marketing and the need for more research and clinical evidence to support the efficacy and safety of these products. It emphasizes the importance of managing blood sugar levels for weight control and overall metabolic health, with a focus on the role of fiber in regulating blood glucose and preventing postprandial spikes. The article also mentions the potential benefits of certain sweeteners, such as stevia, in reducing calorie intake and feelings of hunger, but cautions against the use of sugar alcohols. Overall, the article emphasizes the need for more education and research in this field, as well as investment in dietary strategies and supplements for blood sugar management. [Extracted from the article]
- Published
- 2024
240. Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill
- Author
-
Shanghai High-risk Infants Early Intervention Center
- Published
- 2023
241. Evaluation of Long-term Neurodevelopment in Neonatal Encephalopathy by Infant Treadmill
- Author
-
Shanghai 6F+ Early intervention center for high risk preterm infants
- Published
- 2023
242. Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates
- Published
- 2023
243. Analysis of Volatile Organic Compounds in Patients With Type 1 Diabetes in Induced Hypoglycaemia With a Breath Analyser (VAARABreath)
- Author
-
DCB Research AG and Insel Gruppe AG, University Hospital Bern
- Published
- 2023
244. CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
- Published
- 2023
245. GLP1R-imaging in Hypoglycemia
- Author
-
Rijnstate Hospital
- Published
- 2023
246. Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)
- Author
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Rodolfo Galindo, Principal Investigator
- Published
- 2023
247. Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
- Published
- 2023
248. How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
- Published
- 2023
249. Neuronostatin - a Glucagonotropic Agent in Humans? (NSTCLAMP)
- Author
-
The Novo Nordisk Foundation Center for Basic Metabolic Research and Asger Lund, MD
- Published
- 2023
250. The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes (GIPHYPO)
- Author
-
The Novo Nordisk Foundation Center for Basic Metabolic Research and Asger Lund, Principal investigator, MD, ph.d.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.